Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CTKB Cytek Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: CTKB
Price (delayed)
$3.4
Market cap
$430.64M
P/E Ratio
0
Dividend/share
N/A
EPS
$16,603.78
Enterprise value
$343.71M
Highlights
Cytek Biosciences's EPS has increased by 48% YoY
The debt has contracted by 18% YoY and by 2.7% from the previous quarter
The net income has dropped by 87% since the previous quarter but it is up by 2.2% year-on-year
The quick ratio has contracted by 18% YoY and by 5% from the previous quarter
Cytek Biosciences's equity has decreased by 4.1% from the previous quarter and by 3.3% YoY
Key stats
What are the main financial stats of CTKB
Market
Valuations
Earnings
Shares outstanding
126.66M
Market cap
$430.64M
Enterprise value
$343.71M
Price to earnings (P/E)
0
Price to book (P/B)
1.15
Price to sales (P/S)
2.21
EV/EBIT
N/A
EV/EBITDA
42.8
EV/Sales
1.74
Revenue
$197.05M
Gross profit
$108.25M
Operating income
-$24.76M
Net income
-$11.25M
EBIT
-$2.88M
EBITDA
$8.03M
Free cash flow
$17.61M
Per share
Balance sheet
Liquidity
EPS
$16,603.78
EPS diluted
$16,603.78
Free cash flow per share
$0.14
Book value per share
$2.96
Revenue per share
$1.54
TBVPS
$3.48
Total assets
$482.6M
Total liabilities
$102.97M
Debt
$8.37M
Equity
$379.62M
Working capital
$312.81M
Debt to equity
0.02
Current ratio
5.62
Quick ratio
4.74
Net debt/EBITDA
-10.82
Margins
Efficiency
Dividend
EBITDA margin
4.1%
Gross margin
54.9%
Net margin
-5.7%
Operating margin
-12.6%
Return on assets
-2.3%
Return on equity
-2.9%
Return on invested capital
-1.1%
Return on capital employed
-0.7%
Return on sales
-1.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTKB stock price
How has the Cytek Biosciences stock price performed over time
Intraday
19.3%
1 week
36.55%
1 month
-11.92%
1 year
-37.27%
YTD
-47.61%
QTD
-15.21%
Financial performance
How have Cytek Biosciences's revenue and profit performed over time
Revenue
$197.05M
Gross profit
$108.25M
Operating income
-$24.76M
Net income
-$11.25M
Gross margin
54.9%
Net margin
-5.7%
The net margin has plunged by 90% from the previous quarter
The net income has dropped by 87% since the previous quarter but it is up by 2.2% year-on-year
The operating margin has contracted by 24% from the previous quarter but it has grown by 4.5% YoY
CTKB's operating income is down by 21% from the previous quarter but it is up by 6% YoY
Price vs fundamentals
How does CTKB's price correlate with its fundamentals
Growth
What is Cytek Biosciences's growth rate over time
Valuation
What is Cytek Biosciences stock price valuation
P/E
0
P/B
1.15
P/S
2.21
EV/EBIT
N/A
EV/EBITDA
42.8
EV/Sales
1.74
Cytek Biosciences's EPS has increased by 48% YoY
CTKB's price to book (P/B) is 47% lower than its last 4 quarters average of 1.8
Cytek Biosciences's equity has decreased by 4.1% from the previous quarter and by 3.3% YoY
The P/S is 47% below the last 4 quarters average of 3.5
Efficiency
How efficient is Cytek Biosciences business performance
Cytek Biosciences's return on equity has shrunk by 93% QoQ and by 3.6% YoY
Cytek Biosciences's return on assets has shrunk by 92% QoQ
The return on invested capital has surged by 84% year-on-year
Cytek Biosciences's ROS has soared by 83% YoY
Dividends
What is CTKB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTKB.
Financial health
How did Cytek Biosciences financials performed over time
CTKB's current ratio is down by 20% year-on-year and by 4.1% since the previous quarter
The quick ratio has contracted by 18% YoY and by 5% from the previous quarter
The debt is 98% less than the equity
The debt to equity has contracted by 33% YoY
The debt has contracted by 18% YoY and by 2.7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.